Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to strategic adjustments and the termination of a partnership with a U.S. skincare brand, while focusing on the commercialization of new products [1][2] Financial Performance - In 1H25, the company achieved revenue of 0.66 million yuan, a year-on-year decrease of 30.6% - The net profit attributable to the parent company was -2.39 million yuan, with adjusted net profit at -2.18 million yuan - The gross margin for 1H25 was 48.4%, down by 4.3 percentage points [1] Strategic Adjustments - The revenue decline was attributed to the company's decision to terminate its agency cooperation with the U.S. skincare brand OMA, reallocating resources to new products CU-40102 and CU-10201, which have received regulatory approval - The company is optimistic about accelerating revenue growth in the second half of the year as these core products move towards commercialization [1][2] Cost Management - The company has optimized its expenses, with sales, management, and R&D costs in 1H25 being 0.92 million, 0.64 million, and 0.79 million yuan respectively, showing year-on-year decreases of 11.4%, 5.0%, and 20.3% - The reduction in sales expenses is attributed to improved investment efficiency in multiple products and strategic marketing preparations for upcoming commercialized products [1] Product Pipeline and Future Outlook - The company has made significant progress in its hair and skin care business, with two key products expected to receive market approval in late 2024 and mid-2025 - The company anticipates that the commercialization of these products will enhance growth potential and contribute positively to financial performance [2] - Projections for net profit from 2025 to 2027 are -2.87 million, -1.00 million, and 1.35 million yuan respectively, maintaining a "buy" rating [2]

Core Viewpoint - The company is strategically positioning itself in the hair and skin care market by addressing unmet consumer needs and avoiding highly competitive segments, focusing on localized fat management, hair diseases and care, skin diseases and care, and epidermal anesthesia. Group 1: Hair Care - The demand for hair loss treatment is rapidly increasing in China, with the market previously dominated by minoxidil and oral finasteride, both having significant drawbacks [2] - The company exclusively represents the world's only topical finasteride spray, which enhances transdermal absorption and reduces side effects, with clinical efficacy comparable to oral finasteride [2] - The product CU-40102 is expected to be approved in June 2025 and commercialized by the end of the year, contributing significantly to the company's performance [2] Group 2: Skin Care - The acne treatment market in China is expanding, with traditional treatments facing issues like side effects and antibiotic resistance [2] - The company exclusively represents the world's only topical minocycline foam, overcoming absorption challenges through unique technology [2] - The product CU-10201 is anticipated to be approved in November 2024 and commercialized in the second half of 2025 [2] Group 3: Epidermal Anesthesia - The market for epidermal anesthesia is competitive, with the company aiming to innovate with its lidocaine-dinoprost combination [3] - The traditional lidocaine-dinoprost combination has been ineffective, leading to potential compliance risks for medical institutions [3] - The product CU-30101 has made significant progress and is expected to be the first approved lidocaine-dinoprost cream in China, with NDA submitted in July 2024 [3] Group 4: Localized Fat Management - The localized fat management market is in its early stages, with the company gradually enhancing its product line [3] - Most domestic lipolysis injections are based on deoxycholic acid, while the company is developing a differentiated product using mutated recombinant collagenase, promising improved safety and reduced pain [3] Investment Recommendation - The company has a comprehensive understanding of the skin and hair markets, with a diverse pipeline aligned with market demands, leading to a significant turnaround in performance as key products are launched [3] - Revenue projections for 2025-2027 are estimated at 494 million, 973 million, and 1.45 billion yuan, with net profits expected to shift from losses to a profit of 122 million yuan by 2027, corresponding to a PE ratio of 22 times [3]

Major Events - InnoCare (02577) collaborates with NVIDIA to promote the large-scale implementation of 800 VDC (800-volt direct current) power architecture in AI data centers [1] - Zijin Mining (02899) receives parliamentary approval for the mining lease of Akyem gold mine in Ghana [1] - Codi-B (02487) receives approval from the Hong Kong Department of Health for the market launch of CU-40102 (topical finasteride spray) [1] - China Ruyi (00136) plans to issue a total of 1.3 billion subscription shares at a discount of approximately 4.46%, raising about HKD 38.95 billion [1] - Sinopec Engineering (02386) signs a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia [1] - China Resources Land (01109) and a joint venture with Shanghai Nanfang acquire the Shanghai Yaohua Road project and Yuqingli project for approximately HKD 24.47 billion [1] - Global Industrial Technology (01026) intends to acquire a shopping mall property in Guangzhou's Yuexiu District for no more than HKD 260 million [1] - Corning Jereh Pharmaceutical-B (09966) has its IND application for JSKN022 officially accepted by CDE [1] - Sea Harvest International (01308) signs a shipbuilding contract with Huanghai Shipbuilding for the construction of four container ships [1] - Yika (09923) successfully completes registration as a "credit card number and contract conclusion business operator" in Japan [1] Operating Performance - Far East Horizon (03360) reports a mid-term profit attributable to shareholders of HKD 2.164 billion, an increase of 3.77% year-on-year [1] - Xinyi Energy (03868) reports a mid-term profit attributable to equity holders of HKD 450 million, an increase of 23.43% year-on-year [1] - Xinyi Solar (00968) reports a mid-term profit attributable to shareholders of HKD 746 million, a decrease of 58.8% year-on-year [1] - Xinyi Glass (00868) reports a mid-term profit attributable to shareholders of HKD 1.013 billion, a decrease of 59.64% year-on-year [1] - Xiehe New Energy (00182) continues to reduce financing costs and improve financing capabilities, with significant growth in green electricity business in the first half of the year [1] - PCCW (00008) reports a mid-term loss attributable to shareholders of HKD 445 million, a year-on-year narrowing of 3.68% [1] - Huishang Bank (03698) issues a profit warning, expecting mid-term net profit of approximately HKD 9.3 billion, a year-on-year increase of about 3.8% [1] - BYD (01211) reports sales of approximately 2.4903 million new energy vehicles in the first seven months, a year-on-year increase of 27.35% [1] - NIO-SW (09866) reports cumulative vehicle deliveries of 806,700 units as of the end of July [1] - XPeng Motors-W (09868) delivers 36,717 smart electric vehicles in July, a year-on-year increase of 229% [1] - Li Auto-W (02015) delivers 30,731 new vehicles in July [1] - Geely Automobile (00175) reports total vehicle sales of 237,700 units in July, a year-on-year increase of approximately 58% [1] - Great Wall Motors (02333) reports total vehicle sales of approximately 674,200 units in the first seven months, a year-on-year increase of 3.57% [1]

Group 1: Company Earnings - PCCW (00008.HK) reported a revenue of HKD 18.922 billion for the first half, a year-on-year increase of 7%, with a net loss of HKD 0.445 billion, narrowing by 4% [1] - Xinyi Solar (00968.HK) recorded a revenue of HKD 10.932 billion, a decrease of 6.5% year-on-year, with a net profit of HKD 0.746 billion, down 58.8% [2] - Xinyi Glass (00868.HK) had a revenue of HKD 9.821 billion, a year-on-year decrease of 9.7%, with a net profit of HKD 1.013 billion, down 59.6% [3] - Xinyi Energy (03868.HK) reported a revenue of HKD 1.21 billion, an increase of 7.7% year-on-year, with a net profit of HKD 0.45 billion, up 23.4% [4] - DTXS Silk Road Investment (02510.HK) issued a profit warning, expecting a mid-term net profit of approximately USD 180-200 million, a year-on-year increase of about 220% to 255% [5] - Lianhua Supermarket (00980.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 25-55 million [6] - Tibet Water Resources (01115.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 36 million, a year-on-year increase of about 300% [7] - Foton Motor (00420.HK) issued a profit warning, expecting a mid-term net profit of HKD 30.7 million, turning from loss to profit [8] - Hong Kong Travel (00308.HK) issued a profit warning, expecting a mid-term net loss exceeding HKD 70 million, turning from profit to loss [9] - Poly Property Group (00119.HK) issued a profit warning, expecting a mid-term net profit to decline by 40%-50% year-on-year [10] - Kefu Shan Group Holdings (08512.HK) issued a profit warning, expecting a mid-term net profit to decrease to approximately HKD 43-47 million [11] - Mobi Development (00947.HK) issued a profit warning, expecting a mid-term net loss of approximately HKD 32 million [12] - Changmao Biochemical Engineering (00954.HK) issued a profit warning, expecting a mid-term net loss of approximately HKD 24-27 million [13] - Yunyou Holdings (00484.HK) issued a profit warning, expecting a mid-term net loss to increase to approximately HKD 21 million [14] - Weiya Li (00854.HK) issued a profit warning, expecting a mid-term net profit of approximately HKD 15-25 million, turning from loss to profit [15] Group 2: Automotive Sales - BYD Company (01211.HK) reported sales of approximately 2.4903 million new energy vehicles in the first seven months, a year-on-year increase of 27.35% [16] - Great Wall Motors (02333.HK) reported total vehicle sales of approximately 674,200 units in the first seven months, a year-on-year increase of 3.57% [17] - Li Auto (02015.HK) delivered 30,731 new vehicles in July [18] - Geely Automobile (00175.HK) reported total vehicle sales of 237,700 units in July, a year-on-year increase of approximately 58% [19] Group 3: Company News - Sinopec Engineering (02386.HK) signed a front-end engineering design (FEED) contract for a large green hydrogen project in Yanbu, Saudi Arabia, with a contract value expected to reach several billion USD [20] - InnoCare Pharma (02577.HK) partnered with NVIDIA to jointly promote the large-scale implementation of 800 VDC power architecture in AI data centers [21] - Zijin Mining (02899.HK) received parliamentary approval for the mining lease of the Akyem gold mine in Ghana, with a total transaction value of USD 1 billion [22] - Codex-B (02487.HK) received approval from the Hong Kong Department of Health for the listing of CU-40102 (topical finasteride spray) for the treatment of androgenetic alopecia [23] - Mixue Group (02097.HK) subscribed to a wealth management product from Pudong Development Bank, involving an investment of HKD 300 million [24] Group 4: Buyback Activities - Hang Seng Bank (00011.HK) repurchased 200,000 shares at a cost of approximately HKD 22.5922 million, with repurchase prices ranging from HKD 112.4 to 114.3 [25] - Vitasoy International (00345.HK) repurchased 1.844 million shares at a cost of approximately HKD 16.89 million, with repurchase prices ranging from HKD 9.14 to 9.17 [26]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a moderate recovery in the beauty and cosmetics sector, with a notable performance in hair care and color cosmetics, indicating a stable growth trajectory [7][35] - The medical aesthetics sector is expected to gain momentum from the introduction of innovative products, particularly in the field of collagen and hair loss treatments [30][46] Summary by Sections Market Review - In June, the beauty and personal care index fell by 3.61%, ranking 31st among all primary industries, underperforming the market [14] - The medical aesthetics sector saw significant stock price increases for companies like Meili Tianyuan Medical Health (+64.4%), Yonghe Medical (+50.0%), and Sihuan Pharmaceutical (+13.3%) [20][26] - For the first half of 2025, the medical aesthetics sector recorded substantial gains, with Jinbo Biological (+124.6%), Yonghe Medical (+83.3%), and Meili Tianyuan Medical Health (+69.9%) leading the way [20][26] Medical Aesthetics - Jinbo Biological launched the world's first recombinant type III humanized collagen gel, HiveCOL, which is expected to revolutionize tissue regeneration [30] - Sihuan Pharmaceutical introduced new products targeting skin quality improvement and contour shaping, while Kedi's external finasteride spray received approval, marking a significant advancement in hair loss treatment [31][32] Cosmetics - The retail sales of cosmetics in the first half of 2025 reached 229.1 billion yuan, reflecting a year-on-year growth of 2.9% [35] - Online sales of cosmetics amounted to 267.83 billion yuan, growing by 11.1%, while offline sales decreased by 4.1% to 228.44 billion yuan [36] - The report emphasizes the strong performance of domestic brands in the online market, particularly on platforms like Douyin and Tmall [40][43] Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are expected to gain market share, particularly in high-growth segments [46][47] - Key recommendations include companies like Shangmei Co., Ltd., Maogeping, and Pulaia, which are well-positioned to benefit from the ongoing trends in the beauty market [50]

Core Viewpoint - The recent adjustment of the Hong Kong Stock Connect list has led to a significant impact on the stock price of Kedi-B (02487), which experienced a notable decline followed by a recovery, supported by strong financial performance and market sentiment towards its new product developments [1][3][6]. Stock Performance - Kedi-B's stock price fell by 20.60% over six trading days after being removed from the Hong Kong Stock Connect [1]. - Following a brief recovery, the stock saw a dramatic drop of 26.88% on April 7 due to market volatility, creating a potential buying opportunity [1]. - The stock hit a low of 3.64 HKD on April 9 but rebounded significantly, reaching a peak of 7.62 HKD by May 20, surpassing pre-removal levels [1][3]. Financial Performance - Kedi-B reported total revenue of approximately 280 million RMB for 2024, a year-on-year increase of about 103% [6][7]. - Gross profit for the same period was around 144 million RMB, reflecting a 102% increase year-on-year, while net loss narrowed by 77.91% to approximately 434 million RMB [6][7]. - The company achieved a gross margin of 51.3%, up from 50.6% in the previous year, driven by improved product lines and cost management [8]. Product Line and Market Strategy - The revenue growth was primarily attributed to increased sales of hair care and skincare products, with hair care revenue exceeding 160 million RMB and skincare revenue surpassing 110 million RMB [8]. - Kedi-B plans to enter a second growth phase in 2025 with three significant prescription drugs, including treatments for acne and hair loss, which are expected to drive future revenue growth [9]. - The company is also involved in the development of a botulinum toxin product, CU-20101, which has received approval in South Korea, showcasing its technical capabilities [10][12]. Market Context - The domestic medical aesthetics market is under pressure, with many companies reporting declines in Q1 2025, yet Kedi-B's stock performance indicates positive market sentiment towards its product developments [11]. - The botulinum toxin market in China is projected to reach 11.4 billion RMB by 2025, with a compound annual growth rate of 23.9% from 2020 to 2025, indicating strong growth potential [12][14]. - Kedi-B's entry into the botulinum toxin market, particularly with innovative product forms, positions it well against established competitors [14].